semaglutide oral (RT-116) / Rani Therap - LARVOL DELTA

Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss (OBESITY WEEK 2025) - "This study demonstrates that RT-116 capsules administered orally to awake beagles were safe and well tolerated, delivered semaglutide with high reliability, and were as effective as SC injections as indicated by the relative bioavailability and weight loss. The observed PK-PD relationship, coupled with the absence of treatment-related adverse events and the long track record of clinical safety and efficacy of semaglutide, suggests that RT-116 presents a viable oral alternative to injectable GLP-1 therapies with the potential to expand treatment access and improve patient adherence for the effective management of weight loss and metabolic health."

Presented Preclinical Data on Semaglutide Delivered Orally via RaniPill® at ObesityWeek® 2025. (The Manila Times) - "In November 2025, Rani presented preclinical data demonstrating that oral semaglutide administered via the RaniPill (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration."

Preclinical • Obesity

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025 (The Manila Times)

Preclinical • Obesity

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill HC (GlobeNewswire) - "Rani Therapeutics Holdings...today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor (GLP-1) agonist semaglutide administered via the RaniPill capsule....Eight canines were randomized into two groups who received 0.5mg of semaglutide delivered via oral administration of the RaniPill HC (N=4) or subcutaneous injection (N=4)....Semaglutide was successfully delivered in 7 of 8 canines that received the RaniPill capsule. Semaglutide administered via the RaniPill capsule was well tolerated with no serious adverse events....Initiation of Phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist for the treatment of obesity expected in 2025."

New P1 trial • Preclinical • Metabolic Disorders • Obesity